Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Hackensack, NJ
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Bethlehem, PA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Pittsburgh, PA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Nashville, TN
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Charlottesville, VA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Seattle, WA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
Vaccine Biotherapy of Cancer: Tumor Cells and Dendritic Cells as Active Specific Immunotherapy of Patients With Metastatic Melanoma
Status: Enrolling
Updated:  1/27/2014
Hoag Cancer Center at Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
Vaccine Biotherapy of Cancer: Tumor Cells and Dendritic Cells as Active Specific Immunotherapy of Patients With Metastatic Melanoma
Status: Enrolling
Updated: 1/27/2014
Hoag Cancer Center at Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Immunoablative Protocol for Allogeneic Related and Unrelated Hematopoietic Peripheral Blood Stem Cell Transplant (HPBSC)
Status: Enrolling
Updated:  1/30/2014
Children's Memorial Hospital
mi
from
Chicago, IL
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Immunoablative Protocol for Allogeneic Related and Unrelated Hematopoietic Peripheral Blood Stem Cell Transplant (HPBSC)
Status: Enrolling
Updated: 1/30/2014
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
A Phase I/II Study of Isolated Limb Infusion and Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
Status: Enrolling
Updated:  2/13/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
A Phase I/II Study of Isolated Limb Infusion and Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
Status: Enrolling
Updated: 2/13/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
Status: Enrolling
Updated:  2/18/2014
Stanford University Cancer Institute
mi
from
Palo Alto, CA
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
Status: Enrolling
Updated: 2/18/2014
Stanford University Cancer Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Nanocytology Test to Evaluate Skin Cancer in High Risk Patients
Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients
Status: Enrolling
Updated:  2/27/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Nanocytology Test to Evaluate Skin Cancer in High Risk Patients
Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients
Status: Enrolling
Updated: 2/27/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma
Status: Enrolling
Updated:  3/14/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma
Status: Enrolling
Updated: 3/14/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
EF5 in Melanoma Patients
Pilot Study to Characterize the HRHV Axis in the Microenvironment of Melanoma in Patients Undergoing Isolated Limb Infusion or Hypothermic Isolated Limb Perfusion With Melphalan
Status: Enrolling
Updated:  4/12/2014
Duke Univ Med Ctr
mi
from
Durham, NC
EF5 in Melanoma Patients
Pilot Study to Characterize the HRHV Axis in the Microenvironment of Melanoma in Patients Undergoing Isolated Limb Infusion or Hypothermic Isolated Limb Perfusion With Melphalan
Status: Enrolling
Updated: 4/12/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
A Phase II Trial of the Combination of Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Status: Enrolling
Updated:  5/16/2014
California Cancer Associates For Research,cCARE
mi
from
Encinitas, CA
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
A Phase II Trial of the Combination of Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Status: Enrolling
Updated: 5/16/2014
California Cancer Associates For Research,cCARE
mi
from
Encinitas, CA
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
City of Hope
mi
from
Duarte, CA
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Yale University School of Medicine
mi
from
New Haven, CT
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Loyola University Medical Center
mi
from
Maywood, IL
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Oncology Specialists, SC
mi
from
Park Ridge, IL
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Indiana University Cancer Center
mi
from
Indianapolis, IN
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Local Institution
mi
from
Bronx, NY
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Local Institution
mi
from
Bronx, NY
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Providence Portland Medical Center
mi
from
Portland, OR
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated:  5/27/2014
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases
Status: Enrolling
Updated: 5/27/2014
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated:  8/20/2014
UCSF Medical Center at Mount Zion
mi
from
South San Francisco, CA
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated: 8/20/2014
UCSF Medical Center at Mount Zion
mi
from
South San Francisco, CA
Click here to add this to my saved trials
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated:  8/20/2014
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated: 8/20/2014
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated:  8/20/2014
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated: 8/20/2014
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated:  8/20/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Enrolling
Updated: 8/20/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States
Status: Enrolling
Updated:  9/5/2014
Mount Sinai School of Medicine
mi
from
New York, NY
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States
Status: Enrolling
Updated: 9/5/2014
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Hematology Oncology P.C.
mi
from
Stamford, CT
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Hematology Oncology P.C.
mi
from
Stamford, CT
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Cancer Specialists Of North Florida Beaches
mi
from
Jacksonville, FL
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Cancer Specialists Of North Florida Beaches
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando
mi
from
Orlando, FL
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
University of Chicago
mi
from
Chicago, IL
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Click here to add this to my saved trials